European Leukemia Trial Registry
Trial: RESPONSE 2 (CINC424B2401)

More Details
Title Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus BAT in patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea
Scientific Title Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)
Short Title RESPONSE 2 (CINC424B2401)
Trialgroup NN
Type of Trial multicentric, randomized, prospective, open-label, double-group
Disease Myeloproliferative disease(MPD) Polycythaemia vera
Age >= 18 years
Status Active
Start of Recruitment 01.02.2014
Leader Döhner, Prof. Dr. med., Konstanze
Shortprotocol Shortprotocol
created 21.01.2014 Johannes Kraus
changed 28.11.2014 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org